Uniogen is making real progress in the early detection of ovarian cancer. Our latest study shows that the GLYVAR® Ovarian assays outperform traditional tests, especially in catching cancer early when it matters most. Study shows it: clear improvement compared to CA-125 A newly published study in Clinical… Read More
Finnish-developed test helps detect ovarian cancer earlier, improving treatment options and patient outcomes Globally, ovarian cancer is one of the deadliest cancers affecting women. The GLYVAR® Ovarian I and II glycovariant tests, innovation developed by Uniogen in Turku, Finland, enable earlier detection of ovarian cancer and represent a significant advancement in… Read More
This autumn has been a season of meaningful engagement for Uniogen. We’ve had the opportunity to present our latest research, connect with professionals across continents, and participate in events that shape the future of diagnostics. Here’s a look at where we’ve been and what’s ahead. Next Generation Dx… Read More
This September marks a meaningful milestone: four years since the announcement of the planned merger that eventually united three companies and businesses into what we now proudly call Uniogen. What began as a bold vision to bring together innovative Finnish biotech and life science companies and university spin-offs… Read More
A team from Uniogen cycled to Parainen during World Bicycle Day 2025 June the 3rd is declared as the World Bicycle Day by the UN General Assembly. Inspired by this, we decided to gather a small team of Uniogen employees to ride with bikes from our instrument site, in Turku… Read More
In Uniogen’s hometown, Turku, the biotechnology network is tightly connected, fostering strong collaboration between local biotech companies and the university. This synergy creates a dynamic exchange of knowledge and resources, benefiting both researchers and companies. PhD Shruti Jain from the University of Turku is specialized in developing assays for early cancer… Read More
We’re excited to announce that Uniogen has been granted US Patent for a groundbreaking optical innovation designed to elevate the performance of lateral flow (LF) test strip readers (US Patent No. US12228743B2). At the heart of this invention is a novel optical component that creates a homogenized and freely… Read More
Pioneering research from Uniogen at ESCMID Global 2025: We are excited to announce our participation in ESCMID Global 2025 in Vienna, where our scientists will present their groundbreaking research in C. difficile and B. pertussis diagnostics. This event brings together leading experts in clinical microbiology and infectious diseases, and… Read More
This February, we join the global community in recognizing World Cancer Day, a time to unite and amplify our commitment to reducing the impact of cancer worldwide. For us, it’s a powerful reminder of what we can achieve when we come together for a common cause. Read More
Advancement in product development, accelerated market entry and exhibitions: In 2024, Uniogen experienced an exceptional year marked by significant progress and innovations in research and development in the areas of oncology and new system development. Our R&D teams pushed boundaries, resulting in groundbreaking solutions that can be expected to set… Read More
